-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hypoxia-inducible factor prolyl hydroxylase domain inhibitor (HIF-PHI) is a new approach for the treatment of renal anemia
.
HIF-PHI is thought to increase iron usage to improve the availability of iron for erythropoiesis
Hypoxia-inducible factor prolyl hydroxylase domain inhibitor (HIF-PHI) is a new approach for the treatment of renal anemia
Figure 1: Changes in PLT values and iron content levels on day 0
.
Receiver operating characteristic curves for (a)-ft, (b) TSAT, and (c)-Fe for PLT ≤ 0% rate of change
Figure 1: Changes in PLT values and iron content levels on day 0
Figure 2: Changes in PLT over time in low and high s-ft groups and comparisons between groups
.
PLT was significantly increased in the low s-ft group (*;PFigure 2: Changes in PLT over time in low and high s-ft groups and comparisons between groups
Multivariate analysis showed that PLT rate of change was associated with serum ferritin (s-ft) and red blood cell (RBC) counts [β coefficient; 0.
Table: The relationship between each factor and the rate of change of PLT was analyzed using a linear regression model Table: The relationship between each factor and the rate of change of PLT was analyzed using a linear regression model
Abbreviations: ◁s-Fe; change in serum iron (every 1 μg/dL increase), ◁s-ft; change in serum ferritin (every 1 ng/mL increase), ◁RBC; change in red blood cell count (every 1 × 10 4 /μL increase) ), Rox: Roxda dose (every 1 mg/kg increase), CI; confidence interval
Abbreviations: ◁s-Fe; change in serum iron (every 1 μg/dL increase), ◁s-ft; change in serum ferritin (every 1 ng/mL increase), ◁RBC; change in red blood cell count (every 1 × 10 4 /μL increase) ), Rox: Roxda dose (every 1 mg/kg increase), CI; confidence interval 4
Overall, this study shows that changes in PLT are associated with s-ft and hematopoiesis
.
When the s-ft was 77.
2 ng/mL or higher when converting from DA to Rox, there was less likelihood of increased PLT due to iron levels
Original source:
Ogawa C, Tsuchiya K, Tomosugi N, Maeda K.
Ogawa C, Tsuchiya K, Tomosugi N, Maeda K.
Threshold of Serum Ferritin to Discriminate against Those at Greater Risk of Platelet Increase during Treatment with Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor.
Acta Haematol.
2022 Jan 20.
doi: 10.
1159/000522071 .
Epub ahead of print.
PMID: 35051929.
Ogawa C, Tsuchiya K, Tomosugi N, Maeda K.
Threshold of Serum Ferritin to Discriminate against Those at Greater Risk of Platelet Increase during Treatment with Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor.
Acta Haematol .
2022 Jan 20.
doi: 10.
1159/000522071.
Epub ahead of print.
PMID: 35051929.
Leave a message here